Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL [Phase 1, Phase 2]
Phase I/II clinical trial update describing the study of Rapcabtagene Autoleucel in chronic lymphocytic leukemia, small lymphocytic lymphoma…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL [Phase 2]
Phase 2 clinical trial update examining the efficacy and safety of Pola-ZR-Glo in older treatment-naive patients with Large B-Cell Lymphoma;…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial investigating CD19 CAR-T therapy in newly diagnosed high-risk Large B-cell Lymphoma; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study of lisocabtagene maraleucel for minimal residual disease in patients with Large B-cell …
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma [Phase 3]
This Phase 3 open-label trial compares glofitamab to the Pola-R-CHP regimen in previously untreated Large B-cell lymphoma; the study is curr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL [Phase 2]
This Phase 2 clinical trial update evaluates consolidation of first-line MRD-positive remission with Cema-cel in patients with Large B-cell …
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma [Phase 1, Phase 2]
An exploratory Phase 1/2 clinical trial update evaluating the safety and efficacy of CD19X CAR-T cell injections for relapsed/refractory lar…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: BHB & CAR-T for Lymphomas [NA]
A ClinicalTrials.gov update notes recruitment for a study evaluating beta-hydroxybutyrate (BHB) in combination with CAR-T therapy for Large …
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy [Phase 2]
Phase II trial evaluating loncastuximab tesirine as a consolidation therapy for patients with large B-cell lymphoma who achieved partial res…
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy [Phase 2]
Phase 2 trial evaluating lymphodepletion with ALLO-647 in adults with Relapsed/Refractory Large B-Cell Lymphoma undergoing ALLO-501A allogen…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of C-CAR039 (Prizloncabtagene Autoleucel) for relapsed/refractory large B-cell lympho…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) [Phase 1]
A Phase 1 clinical trial evaluating SC262 in patients with relapsed/refractory Non-Hodgkin's lymphoma, including Large B-cell lymphoma; curr…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study [Phase 2]
A Phase II multicenter trial is evaluating glofitamab in combination with a PD-1 antibody and lenalidomide for relapsed/refractory Large B-c…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating UB-VV400 in combination with rapamycin for relapsed or refractory B-cell malignancies, currently recruitin…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas [Phase 1]
Phase 1 clinical trial evaluating autologous CD22-directed CAR-T cells in patients with recurrent or refractory B-cell lymphomas, including …
-
CLINICAL_TRIALS research · 2025-07-28Clinical Trial Update: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies [Phase 1, Phase 2]
This document outlines a Phase I/II clinical trial of ALETA-001 for various B-cell lymphomas, with recruitment ongoing and sponsored by Canc…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T [Phase 2]
A Phase 2 clinical trial evaluating the combination of Zanubrutinib and Tislelizumab in patients with Large B-cell Lymphoma who progressed a…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial assessing MRD-directed consolidation with Epcor-only or Epcor-R2 after anti-CD19 CAR T-cell therapy for Relapsed/Re…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma
This clinical trial update examines whether different lymphodepletion regimens influence the response to CAR T-cell therapy in relapsed/refr…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of PL001, a CD19 CAR-T cell therapy, for relapsed or refractory B-cell lymphoma. The …
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
This clinical trial registry entry describes a long-term follow-up study of a lentiviral-based gene-edited immune cell therapy for several B…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting [Phase 4]
This Phase 4 trial assesses outpatient administration of Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma, including diffuse lar…
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating a peri-CAR-T cell treatment strategy combining polatuzumab vedotin, obinutuzumab, and glofitamab for Lar…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases [Phase 1]
This clinical trial update outlines the Phase 1 study JWCAR201 for hematology malignancies and autoimmune diseases, which is currently not r…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL [Phase 2]
Phase 2 clinical trial evaluating linperlisib in combination with immunochemotherapy for relapsed/refractory large B-cell lymphoma is curren…